SYMBOL:

    Up to 100 tickers separated by a space
Site Map FAQ Contact us Home Personalize
Company
Industry
Earnings
US Markets
Most Active
Portfolio
Tools
ETFs
Ratings
ARQULE
(NQNM:ARQL Last Sale: 2.19 )
Fundamentals Charts Tech Analysis Industry Earnings
Company Profile   Details

Company Web Site
NQNM: (ARQL : $2.19)
$98 million Market Cap at September 12, 2013
Employs 113.
Biomedics SubIndustry up .00% / Health Industry up .00% Today
19 Presidential Way Research Report Earnings Snapshot - Last 11/10/18
Woburn, MA 01801 Fact Sheet
Phone: (781) 994-0300 Financial Statements
Fax: (781) 395-1225 Peer Comparison
Annual Reports

A. Elia, Chmn., Paolo Pucci, CEO, Peter S. Lawrence, Pres./COO/CFO
Focus is cancer therapeutics. Products include ARQ 501, which is in Phase 2 clinical trials, based on its proprietary Activated Checkpoint Therapy platform for enhancing cell's natural defense mechanism against genetic damage; and ARQ 197, a Phase 1 clinical trial product designed to block cancer cell survival mechanisms and trigger death in cancer cells. Products in the preclinical stage include ARQ-550RP, an E2F Modulation; ARQ-450RP, a Mitotic Checkpoint Activator; and ARQ-350RP, a B-Raf Kinase Inhibitors. Has an alliance with Hoffmann-La Roche. IPO at $12 October 15, 1996. Reported positive trial results on lead experimental lung cancer drug March 31, 2010. Founded in 1993.
Historical Charts    Technical Analysis
No Historical Data available for ARQL

Type of Stock Symbol Last Sale Last Close Net +/- % +/- Low High Volume 52wk Low 52wk High Shares(M)
Common ARQL $2.19 $ 0 $2.19 $2.28 560,801 $1.98 $5.75 44,726
Capitalization
Earnings Summary ()
*** No Earnings Available***
-10121
Common Stock $97,950

A
Google



QUICK NAVIGATION SITE SEARCH   Enter Keyword:
   
Home    Subscribe    Browser Help    Subscriber Services    B-to-B    Banks    Brokerage    Telco    Site Map    Legal    Contact/Email
Copyright © 1996 - 2024 Stock Smart with all rights reserved
Feed is currently being brought back up
Provided by Nanex